Compensatory signaling pathways in tumors confer resistance to targeted therapy, but the pathways and their mechanisms of activation remain largely unknown. We describe a procedure for quantitative proteomics and phosphoproteomics on snap-frozen biopsies of hepatocellular carcinoma (HCC) and matched nontumor liver tissue. We applied this procedure to monitor signaling pathways in serial biopsies taken from an HCC patient before and during treatment with the multikinase inhibitor sorafenib. At diagnosis, the patient had an advanced HCC. At the time of the second biopsy, abdominal imaging revealed progressive disease despite sorafenib treatment. Sorafenib was confirmed to inhibit MAPK signaling in the tumor, as measured by reduced ribosomal protein S6 kinase phosphorylation. Hierarchical clustering and enrichment analysis revealed pathways broadly implicated in tumor progression and resistance, such as epithelial-to-mesenchymal transition and cell adhesion pathways. Thus, we describe a protocol for quantitative analysis of oncogenic pathways in HCC biopsies and obtained first insights into the effect of sorafenib in vivo. This protocol will allow elucidation of mechanisms of resistance and enable precision medicine.
liver | evasive resistance | signal transduction | MAPK | EMT H epatocellular carcinoma (HCC) is a global health concern with an estimated 750,000 new cases per year (1) . In more than 80% of cases, HCC arises in a setting of liver cirrhosis mainly of alcoholic or viral origin (2) . The prognosis for HCC patients is poor, with less than 30% qualifying for curative treatments such as tumor resection or liver transplantation (2) . Median survival time of patients that cannot be treated surgically is less than 1 y. Sorafenib is the only approved targeted therapy for HCC, prolonging median patient survival by ∼3 mo (3) . Sorafenib is a multikinase inhibitor of Raf (B and C), vascular endothelial growth factor receptor (VEGFR), and plateletderived growth factor receptor (PDGFR) (4), which presumably inhibits not only tumor cells but also endothelial cells responsible for tumor vascularization.
Resistance to a targeted cancer drug can be intrinsic or adaptive (5) . Sorafenib is largely cytostatic (6) , suggesting that intrinsic resistance is more common in tumors, although some reports describe tumor shrinkage upon sorafenib treatment (7) . Studies involving HCC cell lines or immunohistochemical staining of tumor sections revealed that sorafenib resistance correlates with the up-regulation of several signaling pathways, including the mammalian target of rapamycin (mTOR) pathway as assayed by S6 S235/236 (8) and Akt S473 phosphorylation (9) . Other potential resistance mechanisms involve epithelial-to-mesenchymal transition (EMT) and autophagy (10, 11). However, the molecular mechanisms of sorafenib resistance in patients are largely unknown. Understanding the pathways that confer intrinsic or adaptive resistance would allow precision medicine and increase treatment efficacy.
Proteomic analysis allows the identification of drug targets for cancer treatment and biomarkers for cancer classification or recurrence. In particular, MS is a powerful tool for resolving the complexity of cancer signaling pathways. With regard to HCC, qualitative proteomics has been performed on resected tumor material (12) , laser-capture microdissected material from tissue sections (13, 14) , and primary hepatocytes or serum derived from patients (15, 16) . These studies (17, 18) identified HCC biomarkers such as glutamine synthetase and heat shock protein 70 (Hsp70) that are currently in use for diagnosis (19, 20) . Quantitative proteomics has been performed on HCC resected tissue and serum (21, 22) . Recently, proteomics has been performed on tumor biopsies of renal cell carcinoma patients (23) . Several studies also have described phosphoproteomic analyses of resected HCC or other cancer material (24) (25) (26) , in some cases quantifying up to 8,000 phosphorylated sites (hereafter referred to as "phosphosites") starting with 2 mg of protein (18, (27) (28) (29) (30) . However, to our knowledge, quantitative proteomics and phosphoproteomics, hereafter collectively referred to as "(phospho)proteomics," have yet to be performed on tumor biopsies, possibly because biopsy material is nonrenewable and typically provides only a very small amount of protein. Importantly, quantitative (phospho)proteomics on serial biopsies taken before and during treatment has not been described. We note that although a biopsy procedure generates less material than a resection, it has the important advantage of capturing normally dynamic properties of a tumor, such as the phosphorylation status of signaling pathways. Biopsies are immediately snap-frozen upon removal from the patient and, unlike resected tissue, are obtained without causing ischemia or hypoglycemia in the collected tissue. Needle biopsies are taken routinely to diagnose and stage the disease. Another important consideration is a method to perform quantitative (phospho)proteomics, such as super-SILAC ("SILAC" is an acronym for Significance Elucidation of evasive resistance to targeted therapies is a major challenge in cancer research. As a proof-of-concept study, we describe quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated hepatocellular carcinoma (HCC) patient. This approach reveals signaling pathway activity in a tumor and how it evades therapy. The described method will allow precision medicine based on phenotypic data. In particular, application of the method to a patient cohort will potentially identify new biomarkers, drug targets, and signaling pathways that mediate evasive resistance.
"stable isotope labeling of amino acids in cell culture"), that allows direct comparison of biopsies obtained at different times or from different patients (31) .
We describe quantitative (phospho)proteomic analyses of needle biopsies of HCC and matched nontumor tissue from a human patient. These analyses provide a global snapshot of signaling pathways in the biopsy material. Analyzing serial biopsies taken from a patient before and during therapy, we measured differences in signaling pathways between tumor and matched nontumor control tissue and the changes in these signaling pathways upon sorafenib treatment. Our findings provide insight into mechanisms of tumor progression and resistance to cancer therapy.
Results
Experimental Setup for Quantitative (Phospho)Proteomics on Biopsies.
To monitor signaling pathways in HCC, we established an experimental protocol to perform (phospho)proteomics on tumor biopsies (Fig. 1A) . The mean wet weight of eight examined biopsies, including biopsies used in pilot experiments, was 21 mg, from which, on average, ∼0.9 mg of total protein was extracted for proteome and phosphoproteome analyses (Fig. 1B) . After testing many permutations (Table S1 ), urea-based protein extraction combined with strong cation exchange chromatography (SCX) and titanium dioxide (TiO 2 ) phosphopeptide enrichment (32) was implemented as the most effective protocol (Fig. 1C) .
To perform quantitative (phospho)proteomics, we generated a spike-in standard consisting of a mixture of cell extracts of five HCC cell lines metabolically labeled with heavy isotopes ( Fig. S1 A and B) . Over 90% of all heavy-to-light (H/L) protein ratios were <1.5 (Fig. S1C) , confirming the high labeling efficiency and thereby the validity of the spike-in standard. From 1 mg of spike-in standard, we could identify ∼4,500 proteins, and nearly all (80%) proteins could be quantified in two of three MS measurements (Fig. S1D) .
To determine the sensitivity of our experimental protocol (Fig.  1C ) on biopsy material, we measured the proteome and phosphoproteome (Datasets S1 and S2) of a liver biopsy from a patient with hereditary hemochromatosis. Approximately 1.4 mg of total protein was extracted from the biopsy, from which ∼5,200 proteins were identified (Fig. 1D) ; 98% of those proteins could be quantified. Approximately 8,500 phosphosites, corresponding to about 3,000 phosphoproteins, were identified (Fig. 1E) ; 92% of those phosphoproteins could be quantified. In total, combining the proteome and phosphoproteome, we were able to quantify ∼6,000 proteins, of which ∼1,800 were found in both datasets (Fig. S1E) . The high percentage of quantified proteins reflects good coverage of the liver biopsy by the spike-in standard (Fig. S1F) . Thus, the spike-in standard was suitable for quantitative (phospho)proteomics on liver biopsies.
Next, we sought to determine the coverage of signaling pathways in our quantified (phospho)proteome. We quantified 234 kinases and several components of prominent signaling pathways involved in HCC, as well as important HCC biomarkers, in the (phospho)proteome (Table S2) . Thus, our overall experimental protocol allows monitoring of cancer-related signaling pathways in liver biopsies.
Quantitative Pre-and On-Therapy (Phospho)Proteomics on Biopsies from a Sorafenib-Treated HCC Patient. Next, we examined if our experimental protocol could quantify signaling changes in an HCC patient upon sorafenib treatment, in particular in ontreatment biopsies compared with pretreatment biopsies. For this proof-ofprinciple study, a 62-y-old male patient with alcoholic liver cirrhosis and an advanced HCC was asked to donate additional biopsies for research purposes ( Fig. 2A) . Biopsies of the primary tumor and control nontumor tissue were taken from the patient 7 wk before sorafenib treatment and then again 14.5 wk later, after 7.5 wk of sorafenib treatment. Shortly thereafter, treatment was stopped, and the patient died 2 mo later. HCC was confirmed by histopathological examination. The pre-and ontreatment tumor biopsies were 50% and 90% HCC, respectively (Fig. 2B ). Blood levels of the HCC biomarker α-fetoprotein (AFP) ( Fig. 2A ) and tumor size increased throughout the observation period. A followup imaging study after 8 wk of sorafenib treatment documented a portal vein occlusion (probable tumor invasion of the portal vein) and ascites, suggesting progressive disease. As a consequence, sorafenib treatment was stopped. The wet weights of the pre-sorafenib control, pre-sorafenib tumor, on-sorafenib control and on-sorafenib tumor biopsies were 40, 11.2, 30.4, and 31.9 mg, which yielded 1.4, 0.17, 1.12, and 0.52 mg of protein, respectively. Thus, the tumor biopsies were smaller and yielded less protein than the control nontumor biopsies (Fig. 3A) , probably because of tumor fibrosis that hampered manipulation.
We analyzed the (phospho)proteome of the tumor and nontumor control biopsies obtained before and during sorafenib treatment (Datasets S3 and S4). In each control biopsy, about 5,000 proteins were identified, of which about 4,000 (∼80%) could be quantified. In agreement with the lower protein yield, the number of proteins identified in the tumor biopsies ranged from 3,000-4,000, of which about 80% could be quantified (Fig. 3A) . Approximately 3,800 phosphorylated sites in about 1,500 phosphoproteins were detected in each control biopsy, and 1,000-2,000 phosphosites in ∼500-1,000 phosphoproteins were detected in the tumor biopsies (Fig. 3B) . The lower number of detected phosphoproteins in the tumor biopsies was again the result of lower protein yields. As expected, the (phospho)proteomes of the tumor and control biopsies largely overlapped ( Fig. S2 A and B) . Finally, combining data from the proteome and phosphoproteome, we quantified 4,379 proteins in, for example, the pre-sorafenib control biopsy in two of three measurements (Fig. S2C ). Of those, 3,365 proteins were measured only in the proteome, 332 proteins were found exclusively in the phosphoproteome, and 682 were in both datasets. These results are comparable to the results obtained with the control biopsy from the hemochromatosis patient analyzed previously (Fig.  S1E) . The slightly lower number of phosphorylated proteins detected in the biopsies from the HCC patient could be explained by reduced tissue quality.
As a proof of principle, we analyzed the expression of the three most common HCC biomarkers, glutamine synthetase, glypican3, and Hsp70 (33) . As shown in Fig. S2 D and E, glutamine synthetase expression was higher in the tumor than in nontumor tissue and increased further upon sorafenib treatment. Glypican3 and Hsp70 were higher in the tumor but only upon sorafenib treatment. This finding suggests that the tumor progressed during sorafenib treatment, in agreement with the observed increase in serum AFP levels and tumor size.
How did quantified protein and phosphorylation levels change significantly between biopsies? As shown in the volcano plots of Fig. S3A , 140 proteins were significantly up-regulated and 142 were down-regulated in the pretreatment tumor compared with the matched nontumor tissue, whereas 290 proteins were up-regulated and 177 were down-regulated in the treated tumor compared with its matched control. With regard to phosphorylation levels (Fig. S3B) , 82 phosphosites were up-regulated and 8 were down-regulated in the pretreatment tumor compared with matched nontumor tissue, and 70 phosphosites were up-regulated and 19 were down-regulated in the treated tumor compared with matched nontumor tissue. Thus, our quantitative analysis of only ∼1 mg of protein recovered from biopsies provided good coverage of the (phospho)proteome and detected significant changes in protein expression and phosphorylation. Importantly, even from a small biopsy containing much less protein (0.17 mg), about 1,010 phosphosites could be detected, of which 424 could be reliably quantified.
Expression and Phosphorylation Clusters in Response to Sorafenib.
We performed unsupervised hierarchical clustering to identify groups of proteins and phosphosites that display similar expression patterns across all four biopsies, i.e., the two nontumor control biopsies and the two tumor biopsies, each minus and plus sorafenib. The heat maps in Fig. 4 display proteins and phosphosites that were quantified in at least two of three measurements per biopsy and that passed an ANOVA-based multisample test for statistically significant up-or down-regulation, with a false discovery rate (FDR) of 2% or 5%. Column-wise clustering of triplicate measurements of a given biopsy demonstrated that interbiopsy biological variation was greater than intrabiopsy experimental variation. Row-wise clustering of proteins and phosphosites (hereafter collectively referred to as "factors") revealed five prominent groups based on tissue distribution and response to sorafenib (Fig. 4 and Datasets S5 and S6). Group 1 contains factors that are decreased in the tumor biopsies relative to nontumor biopsies. These factors could be tumor suppressors whose absence in the tumor conferred intrinsic resistance. Group 2 includes factors that are increased only in the tumor and only before sorafenib treatment. These factors could be oncogenic sorafenib targets. Importantly, phosphorylation of ribosomal protein S6 kinase (Rsk-2)-S369, a site phosphorylated by the MAPK Erk, is in this group (see below). Group 3 consists of factors that are down-regulated specifically in the tumor before treatment. These factors behave as expected for a tumor suppressor whose presence is restored upon sorafenib treatment. Group 4 contains factors that are up-regulated specifically in the tumor upon sorafenib treatment. These are factors possibly involved in tumor progression and adaptive resistance. Members of group 4 could be targeted by a second drug in combination with sorafenib to achieve more effective treatment. Group 5 contains factors that are up-regulated specifically in the tumor biopsies, with and without sorafenib. These could be oncogenic, intrinsic resistance factors. The clinical significance of the factors in the above groups requires further characterization and confirmation.
We performed pathway enrichment analysis on the proteins that could be adaptive resistance factors, i.e., the proteins of group 4 (Fig. S3C) . Using four different over-representation analysis methods, we found several annotation terms that were identified more than once, e.g., lysosome, glycolysis and pyruvate metabolism, apoptosis, and the c-myc pathway. Interestingly, these terms are consistent with the notion that sorafenib inhibits vascularization, thus limiting oxygen and nutrient availability in the tumor.
Changes in MAPK Pathway Activity upon Sorafenib Treatment. We next investigated the effect of sorafenib on its known target in vivo. To this end, we examined phosphorylation changes in the Raf-MAPK/ERK kinase-ERK (Raf-Mek-Erk) MAPK pathway (34) (35) (36) (37) and downstream substrates in the tumor in response to sorafenib (Fig. 5) . In particular, we detected and quantified phosphorylation of C-Raf-S621, B-Raf-S729, Rsk-2-S369, eIF4B (eukaryotic translation initiation factor 4B)-S422, Filamin-A-S2152, raptor-S863 (mTORC1 component), S6-S236, and -S240, and CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase)-S1859. Phosphorylation of the sites in C-Raf and Rsk-2 decreased in the tumor upon sorafenib treatment, albeit significantly only for Rsk-2. This effect, which was even more pronounced when normalized to matched nontumor tissue, indicates that sorafenib treatment inhibited RafErk signaling. Phosphorylation of the pyrimidine biosynthesis protein CAD also decreased in the tumor upon treatment but still remained at a high level. Conversely, phosphorylation of Filamin-A-S2152 and S6-S240 increased in the tumor upon sorafenib treatment. The Filamin-A site appeared as a potential adaptive resistance factor, as revealed by hierarchical clustering of the phosphoproteome (Fig. 4B) . The high level of eIF4B phosphorylation in the tumor both before and during sorafenib treatment suggests that eIF4B may be an intrinsic resistance factor (see above). Finally, B-Raf-S729, raptor-S863, and S6-S236 phosphorylation did not change significantly upon sorafenib treatment. The quantitative decrease in C-Raf and Rsk-2 phosphorylation upon sorafenib treatment suggests that sorafenib indeed inhibited Raf-Erk signaling in the tumor. Importantly, to our knowledge, this is the first demonstration that sorafenib inhibits MAPK signaling in a cancer patient. However, the elevated levels of eIF4B, Filamin-A, S6-S240, and CAD phosphorylation suggest that sorafenib treatment failed to inhibit signaling distal to Rsk-2. This lack of sorafenib responsiveness may suggest that an alternative pathway compensates for the block in Raf-Erk signaling. Further analysis, including a cohort of patients, may reveal the identity of the compensatory pathway and allow betterinformed treatment.
Pathway Enrichment Analysis Reveals Potential Mechanisms of
Sorafenib Resistance. To obtain insight into global changes occurring in the biopsied tissues, two different pathway enrichment analyses were performed using MetaCore (Fig. S4) . In the first analysis ( Fig. S4A and Dataset S7), matched pretreatment tumor and nontumor biopsies were compared directly. The proteome showed a strong enrichment of metabolic pathways, in particular proteins involved in androgen metabolism. Enzymes with a role in the "backdoor" pathway of androgen activation [AKR1C1-3 (Aldo-keto reductase C1-C3)] (38) were up-regulated in the tumor before treatment and increased even further in the tumor following treatment (Fig. S5A and Dataset S3). The enzyme AKR1C3 has been described to increase aggressiveness in prostate cancer (39) . Increased expression of AKR1C3 together with the observed expression of 17β-HSD6, which catalyzes the final step of dihydrotestosterone synthesis (40) , and decreased expression of 17β-HSD2, which inactivates dihydrotestosterone (41), suggests enhanced local production of active androgens and possibly androgen-dependent cancer cell proliferation. We also observed decreased expression of enzymes involved in degradation of such gray, protein quantified in proteome; white, protein not quantified in proteome; blue, phosphosite down-regulated in tumor upon treatment; black, phosphosite unchanged; red, phosphosite up-regulated in tumor upon treatment; red cross, inhibitory phosphosite; black star, phosphosite constitutively high in tumor. (B) Quantitative results (−log 2 -transformed mean ± SD of H/L ratios of each biopsy normalized to control pre-sorafenib biopsy) of prominent signaling nodes from A. S, single ratio measurement only; *, significant in ANOVA-based two-sample test comparing the biopsies, FDR 5% (quantified in at least two of three measurements per biopsy). (C ) Normalized change upon treatment (see Fig. S2D ): −log 2 [(TU/CTRL on-sorafenib)/(TU/CTRL pre-sorafenib)] of prominent signaling nodes from A. *, significant in ANOVA-based multisample test over all four biopsies, FDR 5% (quantified in at least two of three measurements per biopsy).
hormones (UGT2B15, UGT2B17, UGT1A4) in the tumor compared with control tissue, likely indicating a loss of liver-specific characteristics (42) . Interestingly, elevated levels of active androgens represent a well-described risk factor for HCC development, accounting for the higher incidence of HCC among males (43) . Finally, the proteome also was enriched in immune response pathways, possibly indicative of inflammation in the tumor. The phosphoproteome exhibited enrichment in pathways involved in cell adhesion, translation, and insulin signaling, all pathways commonly implicated in cancer.
In the second analysis ( Fig. S4B and Dataset S8), we compared tumor tissue obtained before and during sorafenib treatment. In this case, changes were normalized to the matched nontumor control tissues (Fig. S2D) . This analysis identifies changes that are sorafenib-induced or changes caused by tumor progression; it is not possible to distinguish these two scenarios, because untreated biopsies from the second time point are not available. The proteome displayed a strong enrichment of pathways involved in central carbon metabolism, suggesting an increase in glycolysis and a decrease in Krebs cycle components in the sorafenib-treated tumor. The increased glycolytic enzymes were aldolase, enolase, and pyruvate kinase; the decreased Krebs cycle enzymes were isocitrate dehydrogenase, α-ketoglutarate dehydrogenase, and succinate dehydrogenase (Dataset S3). This finding is in agreement with the recent observation that increased glycolysis correlates with sorafenib resistance (44) and that sorafenib inhibits vascularization. Furthermore, both the proteome and phosphoproteome revealed enrichment of pathways involved in cell proliferation, including the MAPK pathway, as described above (Fig. 5) .
Both MetaCore analyses revealed significant enrichment of cell adhesion pathways (Fig. 6 and Fig. S5B ). Interestingly, vimentin and the extracellular matrix (ECM) proteins fibronectin and vitronectin were up-regulated, and desmoplakin, plakoglobin, the junctional adhesion molecules JAM-1/2 and zona occludens-1 (ZO-1), the putative tumor suppressor p120 catenin, and the cytoskeleton regulator α-catenin were down-regulated in the tumor upon treatment. Collectively, these changes suggest that EMT occurred in the tumor, during tumor progression and/or in response to sorafenib (45, 46) . Importantly, EMT correlates with sorafenib resistance and tumor invasiveness (10, 47), whereas the ECM plays a role in drug resistance in a process called "cellular adhesion molecule-dependent drug resistance" (CAM-DR) (48, 49) . Both processes may have contributed to increased tumor invasiveness and the failure of sorafenib treatment in the patient. In agreement with this notion, a portal vein occlusion (probable tumor invasion of the portal vein), a finding interpreted as progressive disease, was observed in the patient after 8 wk of sorafenib treatment.
Discussion
We describe a protocol for quantitative (phospho)proteomic analysis of needle biopsies. We used this protocol to examine control and tumor biopsies obtained from an HCC patient before and during sorafenib treatment. The small, needle biopsies yielded 0.17-1.4 mg of protein from which we were able to quantify 2,000-4,000 proteins and 500-2,100 phosphosites. To our knowledge, this is the first quantitative phosphoproteomic analysis of serial biopsies from a cancer patient. Phosphorylation in the Raf-Erk-Rsk pathway was reduced in the sorafenibtreated tumor, indicating that the drug was indeed effective in inhibiting its target kinase, Raf. Interestingly, phosphorylation of downstream targets was not similarly inhibited, suggesting that a compensatory pathway(s) may have been active in the tumor, possibly accounting for the treatment failure observed in the patient. Pathway enrichment analysis suggests EMT and CAM-DR as processes potentially involved in tumor progression and treatment failure. The protocol described here could eventually be translated to the clinic to provide precision therapy and thus more effective treatment of patients.
Studies analyzing phosphorylation in biopsies thus far have used antibody-based immunohistochemistry, immunoblotting, or reverse-phase protein arrays (8) . In contrast, our protocol allows quantitative analysis of multiple pathways in parallel and even the detection of new phosphorylation sites. A critical factor is the quality of the biopsy material. The coaxial needle biopsy technique used allows sampling multiple times at the same site on the tumor. It is essential that one of the biopsy samples is evaluated by a pathologist for diagnosis and grading of the HCC. Importantly, the pathologist also provides information on the relative amounts of vital tumor cells, stromal cells, fibrosis, and sclerosis in the biopsy, and the amount of nonmalignant liver tissue. An accurate pathological evaluation is even more important for biopsies of infiltrative type HCC that often do not have discrete boundaries in imaging studies. Based on the results of the pathological assessment, one can determine whether HCC biopsies obtained at different times during disease progression can be compared. For serial biopsies before and during treatment, we sampled the same tumor nodule. However, tumor shape can change over time. Given this limitation in the serial biopsy procedure, it is imperative to use robust statistics for the analysis of (phospho)proteomic data. Only changes of more than twofold or changes rated as significant by ANOVA-based tests are taken into consideration. Importantly, we did not observe a bias toward up-or down-regulated proteins that could be correlated with the percentage of tumor tissue present in the biopsy.
We obtained evidence for EMT and up-regulation of ECM proteins in the tumor upon treatment. This finding suggests that the tumor progressed toward a more aggressive and invasive phenotype. Indeed, the patient displayed portal vein occlusion (probably caused by tumor invasion of the portal vein), suggesting progressive disease. Furthermore, EMT and the upregulation of ECM proteins could be one of the potential compensatory pathways driving progression of HCC upon sorafenib treatment, as observed in the patient. Data from a cohort of patients will provide a more complete picture of how HCC progresses and the mechanisms of sorafenib resistance. The CYTOSKELETON REMODELING P P P P P P Fig. 6 . Pathway enrichment analysis indicates EMT upon sorafenib treatment. Pathway map of junctional mechanism of cell adhesion generated using MetaCore (Fig. S4) . The left half of the protein icon and the left phosphate group represent tumor vs. control pre-sorafenib; the right half of the protein icon and the right phosphate group indicate normalized change upon treatment (see Fig. S2D ); white, not detected; gray, not significantly changed; blue, significantly reduced more than 0.75-fold (log 2 ); red, significantly increased more than 0.75-fold (log 2 ).
described protocol could facilitate the search for new therapeutic options for HCC and also could be applied to other cancers treated with other drugs to further the understanding of carcinogenesis and cancer drug resistance in general. Another future perspective is to identify predictive molecular patterns that would aid in patient stratification.
Materials and Methods
Study Design and Patient Biopsy Selection. Patients were recruited in the Clinic for Gastroenterology and Hepatology of the University Hospital Basel, Switzerland. They gave written informed consent to donate liver biopsy specimens for research. The pilot experiment biopsies and the hemochromatosis patient biopsy were collected to build up a biobank; the HCC patient biopsies were collected as part of a study protocol, number EK 152/10. Both protocols were approved by the Ethics Committee of the Canton Basel, Switzerland. The biopsies were performed under ultrasound guidance using a coaxial needle technique allowing repetitive sampling from the same part of a focal lesion with a full-core biopsy instrument (BioPince; Angitech). Diagnosis of HCC was made by histopathological analysis.
Other Methods. For further information on materials and methods, see SI Materials and Methods.
